<DOC>
	<DOCNO>NCT02816762</DOCNO>
	<brief_summary>Objectives : Main objective : To assess effect 12 month CPAP treatment add conventional drug treatment albuminuria patient diabetic nephropathy obstructive sleep apnea ( OSA ) . Secondary objective : To evaluate effect CPAP treatment estimate glomerular filtration rate patient diabetic nephropathy OSA ; determine additional longterm CPAP effect glycemic control , insulin resistance , lipid profile , health-related quality life biomarkers cardiac function , inflammation , oxidative stress , sympathetic tone appetite-regulating hormone patient diabetic nephropathy OSA ; identify subgroup patient diabetic nephropathy OSA 12 month treatment CPAP achieve pronounce reduction albuminuria . Methodology : Randomized , multicenter , non-blinded , parallel group , conventional treatment-controlled trial 12 month duration . Subjects randomize conventional dietary pharmacological treatment conventional dietary pharmacological treatment plus continuous positive airway pressure ( CPAP ) . Study subject : Subjects 18 80 year overweight obesity clinical diagnosis diabetic nephropathy , increase urinary albumin/creatinine ratio 30 mg/g estimate glomerular filtration rate &gt; 20 ml/min/1.73 m2 , treatment stable dose angiotensin-converting enzyme ( ACE ) inhibitor , angiotensin II receptor blocker ( ARBs ) anti-aldosterone drug last four week . Efficacy variable : urinary albumin/creatinine ratio estimate glomerular filtration rate ; glycosylated hemoglobin ( HbA1c ) ; fast glucose insulin ; homeostatic model assessment ( HOMA ) QUICKI index ; total cholesterol , HDL-cholesterol , LDL-cholesterol , triglycerides ; Troponin I , proBNP , homocysteine high-sensitivity C-reactive protein ; systemic biomarkers ( inflammation [ IL-6 , IL-8 tumor necrosis factor-α ] , oxidative stress [ 8-isoprostane ] , endothelial damage [ endothelin , VCAM-1 ICAM-1 ] , sympathetic activity [ neuropeptide Y ] appetite-regulating hormone [ leptin adiponectin ] ) clinical questionnaire : short form ( SF ) -12 , EuroQoL iPAQ .</brief_summary>
	<brief_title>CPAP Effect Albuminuria Patients With Diabetic Nephropathy Obstructive Sleep Apnea</brief_title>
	<detailed_description />
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Albuminuria</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<mesh_term>Enzyme Inhibitors</mesh_term>
	<mesh_term>Angiotensinogen</mesh_term>
	<mesh_term>Angiotensin II</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<criteria>Subjects age 18 80 year old Overweight obesity ( BMI ≥25 kg/m2 ) Previous diagnosis type 2 diabetes , fulfil least one follow criterion : 1 ) current treatment oral antidiabetic drug and/or insulin ; 2 ) fast glucose value 126 mg/dl least 2 occasion ; 3 ) blood glucose level 2 hour oral glucose tolerance test equal 200 mg/dl ; 4 ) glycated hemoglobin ( HbA1c ) level &gt; 6.5 % Clinical diagnosis diabetic nephropathy , urinary albumin/creatinine ratio &gt; 30 mg/g estimate glomerular filtration rate 20 ml/min per 1.73 m2 . Treatment stable dos angiotensinconverting enzyme inhibitor , angiotensin II receptor blocker antialdosterone agent last four week . Non diabetic nephropathy ( confirm biopsy ) . Dialysis acute renal failure within 6 previous month . Evidence clinic history relevant bilateral stenosis renal artery ( &gt; 75 % ) Urinary albumin/creatinine ratio high 3000 mg/g , baseline visit . Systolic blood pressure ≥ 180 mmHg diastolic blood pressure ≥ 110 mm Hg baseline visit . Stroke , transient ischemic attack , acute coronary syndrome , hospitalization heart failure worsening , within previous 30 day . Professional driver , risk profession respiratory failure . Severe daytime sleepiness ( Epworth sleepiness scale &gt; 18 ) Concomitant treatment high dose acetylsalicylic acid ( &gt; 500 mg/day ) continuous treatment nonsteroidal antiinflammatory drug Previous treatment CPAP Participation another clinical trial within 30 day prior randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>CPAP</keyword>
	<keyword>Sleep apnea</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Nephropathy</keyword>
	<keyword>Albuminuria</keyword>
</DOC>